Amylyx Pharmaceuticals, Inc.AMLX

Market cap

$194.45M

P/E ratio

	Dec 31, 2022
Net loss	-198
Stock-based compensation expense	22
Depreciation	0
Amortization (accretion) of investment premiums (discounts)	2
Accounts receivable, net	15
Inventories	10
Interest receivable	-0
Prepaid expenses and other current assets	5
Operating lease right-of-use assets	2
Other assets	0
Accounts payable	2
Accrued expenses and deferred rent	26
Operating lease liabilities	-1
Net cash used in operating activities	-180
Purchases of property and equipment	3
Purchases of investments	416
Proceeds from maturities of short-term investments	179
Net cash used in investing activities	-239
Proceeds from initial public offering	201
Proceeds from follow-on offering	232
Initial public offering costs paid	2
Follow-on offering costs paid	1
Proceeds from Stock Options Exercised	2
Net cash provided by financing activities	432
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents	-0
Net increase in cash, cash equivalents and restricted cash equivalents	13
Unrealized Gain (Loss) on Investments	0
Purchases of property and equipment included in accounts payable	0
Right-of-use assets and liabilities upon ASC842 adoption	2
Right-of-use assets obtained in exchange for lease liabilities	5
Movement of deferred offering costs to equity	5
Follow-on offering costs included in accounts payable and accrued expenses	0
Conversion of preferred stock to common stock upon initial public offering	239
Income taxes paid	0